Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Magnevist

(Gadolinium)

Phase 2Small molecule

OOHSU Knight Cancer Institute

Gadolinium is a contrast agent used during MRI scans to help doctors see certain body structures and tissues more clearly by making them appear brighter in the images.[1] Magnevist is currently being investigated across 23 indications[3], with its most advanced program in Phase 2.[1]

Magnevist is one of 571 small molecule programs targeting Cervical Dystonia. It is currently in Phase 2.

23

Indications

28

Total Trials

6

Active Trials

570

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical DystoniaActive, not recruiting

Uterine LeiomyosarcomaActive, not recruiting

ParagangliomaActive, not recruiting

SpasticityActive, not recruiting

RadiculopathyActive, not recruiting

Inborn Error of ImmunityActive, not recruiting

Alzheimer DiseaseActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

SepsisActive, not recruiting

Neurofibromatosis Type 1Active, not recruiting

Cervical DystoniaPhase 1/Phase 2

Active, not recruiting

Uterine LeiomyosarcomaPhase 2

Active, not recruiting

ParagangliomaPhase 1

Active, not recruiting

SpasticityPhase 1/Phase 2

Active, not recruiting

RadiculopathyPreclinical

Active, not recruiting

Inborn Error of ImmunityPhase 1

Active, not recruiting

Alzheimer DiseasePreclinical

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 1

Active, not recruiting

SepsisPreclinical

Active, not recruiting

Neurofibromatosis Type 1Preclinical

Active, not recruiting

Showing 10 of 22 indications

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Magnevist

OOHSU Knight Cancer Institute

Novantrone

Mekinist

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Ranexa

MMenarini International Operations Luxembourg SA

Viagra

VViatris Specialty LLC

Prednisone/prednisolone

Triptorelin Pamoate

Statin

Bristol-Myers Squibb

Therapeutic Hydrocortisone

EEastern Cooperative Oncology Group

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Brain Tumors

NCT03067467

Q2 2027

Phase 1Recruiting

Imaging

NCT02648009

Q3 2027

Phase 1Active, not recruiting

Acute Myeloid Leukemia

NCT02390635

Q2 2028

Phase 2Recruiting

Brain Metastases

NCT05692635

Clinical

Trials by Indication[1]

Brain Tumors4 trials

Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases

Completed·OOHSU Knight Cancer Institute·N/A·NCT00103038·155 enrolled

Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

Recruiting·UUniversity of Texas Southwestern Medical Center··NCT03067467·25 enrolled

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00659126·40 enrolled

Show 1 more trial

DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors

Completed·OOHSU Knight Cancer Institute·Phase 1·NCT00978562·14 enrolled

Glioblastoma2 trials

Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma

Completed·SStanford University·Phase 1·NCT04474353·12 enrolled

Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery

Withdrawn·OOhio State University Comprehensive Cancer Center·N/A·NCT02590497

ESS1 trial

A Feasibility Study to Assess the Use of Gadolinium in Computed Tomography

Withdrawn·MMassachusetts General Hospital·Phase 4·NCT02163005

Acute Myeloid Leukemia1 trial

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT02390635·77 enrolled

Spasticity1 trial

ASIS for Botox in Upper Limb Spasticity

Unknown status·Lli nguyen·Phase 1/2·NCT02074150·60 enrolled

19 more indications

AIN1 trial

Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease

Terminated·UUniversity Hospital, Grenoble·Phase 4·NCT02530931·23 enrolled

Prostate Cancer1 trial

18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer

Approved for marketing·SStanford University··NCT04809584

Brain Metastases1 trial

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Recruiting·WWake Forest University Health Sciences·Phase 2·NCT05692635·60 enrolled

Psoriasis1 trial

ASIS for Enbrel in Plaque Psoriasis

Unknown status·AASIS Corporation·Phase 1/2·NCT02112097·60 enrolled

Chronic1 trial

Chronic Convection Enhanced Delivery of Topotecan

Completed·—·Phase 1·NCT03154996·5 enrolled

Acromegaly1 trial

Cardiac (CMRI) Assessment of Acromegaly

Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT02948322·28 enrolled

Allograft1 trial

Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction

Completed·PPaul Kim·Phase 4·NCT02597543·14 enrolled

Glioblastoma Multiforme1 trial

MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy

Completed·OOHSU Knight Cancer Institute·N/A·NCT00660543·14 enrolled

Imaging1 trial

Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection

Recruiting·SSunnybrook Health Sciences Centre·Phase 1·NCT02648009·112 enrolled

Migraine1 trial

ASIS for Botox in Chronic Migraine

Unknown status·AASIS Corporation·Phase 1/2·NCT02074163·60 enrolled

Sepsis1 trial

Severe Sepsis in Children - IMPRESS-C

Withdrawn·UUniversity of Florida··NCT02598674

Heart Disease1 trial

Comprehensive Evaluation of Ischemic Heart Disease Using MRI

Completed·NNorthwestern University·Phase 2/3·NCT01234870·40 enrolled

Central Nervous System1 trial

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

Recruiting·OOHSU Knight Cancer Institute·Phase 2·NCT03270059·150 enrolled

Pilot Study1 trial

Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study

Completed·—·Phase 1·NCT02783768·12 enrolled

Cervical Dystonia1 trial

ASIS for Botox in Cervical Dystonia

Unknown status·Lli nguyen·Phase 1/2·NCT02074293·60 enrolled

Injury1 trial

Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults

Withdrawn·UUniversity of Florida··NCT02599844

Epilepsy1 trial

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

Recruiting·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT02531880·40 enrolled

LMS - Leiomyosarcoma1 trial

Phase 2 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Gemcitabine Followed by Systemic Adjuvant Chemotherapy With Dacarbazine for Locally Recurrent Uterine Leiomyosarcoma (LMS)

Completed·SStanford University·Phase 2·NCT04727242·17 enrolled

Unspecified1 trial

Use of Gadolinium in CT Pulmonary Angiography

Withdrawn·MMassachusetts General Hospital·Phase 4·NCT02234375

Sources

References

[1]
ClinicalTrials.gov — 28 trial records for Gadolinium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gadolinium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gadolinium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — OHSU Knight Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOHSU Knight Cancer Institute

Related News